Inactive Instrument

Medifocus, Inc.

Equities

MDFZF

CA58470Q1019

Medifocus Inc. Appoints William Jow as Chief Executive Officer to Replace Augustine Y. Cheung

October 03, 2016 at 05:12 pm

Medifocus Inc. announced the appointment of William Jow, M.D. to the position of Chief Executive Officer, effective October 1, 2016, replacing Augustine Y. Cheung, Ph.D., the founder of the company. Dr. Jow has been in private practice for over 20 years, and has been Chairman of Urology at Hackensack Meridian Health - Bayshore Hospital in Holmdel, New Jersey, and served on its Medical Executive Committee since 2012.

Latest news about Medifocus, Inc.

Medifocus Inc. Announces Resignation of Mirsad Jakubovic as Chief Financial Officer	21/08/20	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019	02/03/20	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019	29/11/19	CI
Medifocus Inc. Reports Earnings Results for the First Quarter Ended June 30, 2019	29/08/19	CI
Medifocus Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	30/07/19	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	28/02/19	CI
Medifocus, Inc. Announces Global Market Expansion with Prolieve Performed and Reimbursed by Insurance Carriers in Hong Kong	03/01/19	CI
Medifocus, Inc. Announces FDA PMA Supplement Approval for New Labeling	03/12/18	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2018	13/11/18	CI
Medifocus Inc. Reports Unaudited Consolidated Earnings Results for the Quarter Ended June 30, 2018	13/09/18	CI
Medifocus, Inc. Announces Successful Completion of FDA Post Approval Study for the Prolieve (R) Thermodilatation(Tm) System	05/06/18	CI
Medifocus Inc. Enters into an Exclusive Distribution Agreement with Amos Gazit, Ltd to Market and Distribute Proven Prolieve® Thermodilatation System	09/01/18	CI
Medifocus, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2017	28/08/17	CI
Medifocus, Inc. Auditor Raises 'Going Concern' Doubt	30/07/17	CI
Medifocus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016	16/03/17	CI
Medifocus Inc. Reports Operating Results for the Six Months Ended September 30, 2016	19/12/16	CI
Medifocus Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended September 30, 2016	07/12/16	CI
Medifocus Inc. Appoints William Jow as Chief Executive Officer to Replace Augustine Y. Cheung	03/10/16	CI
Medifocus Inc. Announces Board Changes	14/09/16	CI
Medifocus Inc. Announces Earnings Results for the First Quarter Ended June 30, 2016	14/09/16	CI
Medifocus Inc. Auditor Raises 'Going Concern' Doubt	09/06/16	CI
Medifocus Inc.(TSXV:MFS) dropped from S&P/TSX Venture Composite Index	18/01/16	CI
Medifocus Inc. Signs Research &Development and Manufacturing Agreement with Yuanxing Bio-Pharm Science &Technology Co. Ltd	13/01/16	CI
Medifocus Inc. announced that it has received $0.79 million in funding	13/12/15	CI
Medifocus Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2015	07/12/15	CI

Chart Medifocus, Inc.

Duration

Period

More charts

Company Profile

Medifocus, Inc. is a Canada-based biotechnology company holding a portfolio of medical products encompassing thermotherapy systems. The Company develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostate Hyperplasia (BPH). It owns two focused heat technology platforms: The Endo-thermotherapy Platform and The Adaptive Phased Array (APA) Microwave Focusing Platform. The Endo-thermotherapy Platform from which Prolieve Thermodilatation System (Prolieve) was developed, can potentially be used to treat cancers in prostate, rectal, cervical and esophageal. The APA Microwave Focusing Platform directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company's APA 1000 Breast Cancer Treatment System was developed from the APA technology platform.

Sector

More about the company